Literature DB >> 28529318

Neurodegenerative disorders: Ataxin 2 reduction rescues motor defects.

Sarah Crunkhorn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28529318     DOI： 10.1038/nrd.2017.104

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.

Authors:  Daniel R Scoles; Pratap Meera; Matthew D Schneider; Sharan Paul; Warunee Dansithong; Karla P Figueroa; Gene Hung; Frank Rigo; C Frank Bennett; Thomas S Otis; Stefan M Pulst
Journal:  Nature       Date:  2017-04-12       Impact factor: 49.962

2.  Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.

Authors:  Lindsay A Becker; Brenda Huang; Gregor Bieri; Rosanna Ma; David A Knowles; Paymaan Jafar-Nejad; James Messing; Hong Joo Kim; Armand Soriano; Georg Auburger; Stefan M Pulst; J Paul Taylor; Frank Rigo; Aaron D Gitler
Journal:  Nature       Date:  2017-04-12       Impact factor: 69.504
  2 in total
  1 in total

1.  Proteomic analysis of the effect of the polyphenol pentagalloyl glucose on proteins involved in neurodegenerative diseases in activated BV‑2 microglial cells.

Authors:  Patricia Mendonca; Equar Taka; Karam F A Soliman
Journal:  Mol Med Rep       Date:  2019-06-19       Impact factor: 3.423
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.